7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo[d]azepine derivatives with 5-ht6 receptor affinity for the treatment of cns disorders
Номер патента: EP1487801A1
Опубликовано: 22-12-2004
Автор(ы): Christopher Norbert GlaxoSmithKline JOHNSON, David R GlaxoSmithKline WITTY, Shahzad Sharooq GlaxoSmithKline RAHMAN, Stephen Frederick GlaxoSmithKline MOSS, Steven Mark Bromidge
Принадлежит: Glaxo Group Ltd
Опубликовано: 22-12-2004
Автор(ы): Christopher Norbert GlaxoSmithKline JOHNSON, David R GlaxoSmithKline WITTY, Shahzad Sharooq GlaxoSmithKline RAHMAN, Stephen Frederick GlaxoSmithKline MOSS, Steven Mark Bromidge
Принадлежит: Glaxo Group Ltd
Реферат: The present invention relates to novel sulfonamide compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
Номер патента: US20230277505A1. Автор: Hongmei Li,Sonja Strah-Pleynet,Bradley Teegarden,Peter I. Dosa,Honnappa Jayakumar. Владелец: Arena Pharmaceuticals Inc. Дата публикации: 2023-09-07.